PMID- 19744042
OWN - NLM
STAT- MEDLINE
DCOM- 20091104
LR  - 20240402
IS  - 1750-3639 (Electronic)
IS  - 1015-6305 (Print)
IS  - 1015-6305 (Linking)
VI  - 19
IP  - 4
DP  - 2009 Oct
TI  - EGFRvIII-targeted vaccination therapy of malignant glioma.
PG  - 713-23
LID - 10.1111/j.1750-3639.2009.00318.x [doi]
AB  - Given the highly infiltrative growth pattern of malignant glioma and the lack of 
      specificity associated with currently available treatment regimens, alternative 
      strategies designed to eradicate cancer cells while limiting collateral toxicity 
      in normal tissues remain a high priority. To this end, the development of 
      specific immunotherapies against targeted neoplastic cells represents a promising 
      approach. The epidermal growth factor receptor class III variant (EGFRvIII), a 
      constitutively activated mutant of the wild-type tyrosine kinase, is present in a 
      substantial proportion of malignant gliomas and other human cancers, yet 
      completely absent from normal tissues. This receptor variant consists of an 
      in-frame deletion, the translation of which produces an extracellular junction 
      with a novel glycine residue, flanked by amino acid sequences that are not 
      typically adjacent in the normal protein. In this review, both preclinical and 
      early clinical development of a peptide vaccine directed against this portion of 
      the EGFRvIII antigenic domain are recapitulated. Following vaccination, our group 
      has demonstrated potent, redirected cellular and humoral immunity against cancer 
      cells expressing the mutant receptor without significant toxicity. Additionally, 
      the corresponding therapeutic outcomes observed in these studies lend credence to 
      the potential role of peptide-based vaccination strategies among emerging 
      antitumor immunotherapies in patients with malignant glioma.
FAU - Choi, Bryan D
AU  - Choi BD
AD  - Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of 
      Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. 
      bryan.choi@duke.edu
FAU - Archer, Gary E
AU  - Archer GE
FAU - Mitchell, Duane A
AU  - Mitchell DA
FAU - Heimberger, Amy B
AU  - Heimberger AB
FAU - McLendon, Roger E
AU  - McLendon RE
FAU - Bigner, Darell D
AU  - Bigner DD
FAU - Sampson, John H
AU  - Sampson JH
LA  - eng
GR  - R01 CA097222-03/CA/NCI NIH HHS/United States
GR  - R01 CA097611-03/CA/NCI NIH HHS/United States
GR  - K23 RR016065-01/RR/NCRR NIH HHS/United States
GR  - R01 CA097611-04/CA/NCI NIH HHS/United States
GR  - K23 RR016065-04/RR/NCRR NIH HHS/United States
GR  - R01 CA097222-02/CA/NCI NIH HHS/United States
GR  - K23 RR016065-02/RR/NCRR NIH HHS/United States
GR  - R01 CA097222-05/CA/NCI NIH HHS/United States
GR  - R01 CA097611-02/CA/NCI NIH HHS/United States
GR  - R01 CA097611/CA/NCI NIH HHS/United States
GR  - K23 RR016065-05/RR/NCRR NIH HHS/United States
GR  - R01 CA097222/CA/NCI NIH HHS/United States
GR  - R25 NS065731/NS/NINDS NIH HHS/United States
GR  - K23 RR016065/RR/NCRR NIH HHS/United States
GR  - R01 CA097222-01/CA/NCI NIH HHS/United States
GR  - R01 CA235612/CA/NCI NIH HHS/United States
GR  - R01 CA097222-04/CA/NCI NIH HHS/United States
GR  - R01 CA097611-05/CA/NCI NIH HHS/United States
GR  - R25 NS065731-01/NS/NINDS NIH HHS/United States
GR  - K23 RR016065-03/RR/NCRR NIH HHS/United States
GR  - P20 CA096890-010003/CA/NCI NIH HHS/United States
GR  - R01 CA097611-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Brain Pathol
JT  - Brain pathology (Zurich, Switzerland)
JID - 9216781
RN  - 0 (Cancer Vaccines)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Brain Neoplasms/immunology/*therapy
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Clinical Trials as Topic
MH  - ErbB Receptors/*immunology
MH  - Glioblastoma/immunology/*therapy
MH  - Humans
MH  - Immunotherapy
PMC - PMC2846812
MID - NIHMS181907
EDAT- 2009/09/12 06:00
MHDA- 2009/11/05 06:00
PMCR- 2009/09/04
CRDT- 2009/09/12 06:00
PHST- 2009/09/12 06:00 [entrez]
PHST- 2009/09/12 06:00 [pubmed]
PHST- 2009/11/05 06:00 [medline]
PHST- 2009/09/04 00:00 [pmc-release]
AID - BPA318 [pii]
AID - 10.1111/j.1750-3639.2009.00318.x [doi]
PST - ppublish
SO  - Brain Pathol. 2009 Oct;19(4):713-23. doi: 10.1111/j.1750-3639.2009.00318.x.